Clinical outcomes of retreatment with daratumumab-based regimens in anti-CD38 refractory multiple myeloma.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.7570
Abstract: 7570 Background: Daratumumab (Dara)-based regimens have resulted in deep responses and improved outcomes in newly diagnosed (NDMM) and relapsed/refractory multiple myeloma (RRMM). As the use of dara has increased in both settings, understanding the utility… read more here.
Keywords: dara based; refractory; therapy; pts received ... See more keywords